CeMM
CeMM is a Vienna-based, ÖAW-owned non-profit research institute conducting post-genomic molecular medicine to elucidate human disease mechanisms, serving the international scientific community via publications, open-source AI tools, and biotech spin-offs.
- Company typePrivate
- Founded2005
- HeadquartersVienna, Austria
- Headcount101–250
- GTM typeB2B
- OfferingServices
What CeMM does
CeMM Research Center for Molecular Medicine GmbH is a Vienna-based, non-profit basic research institute founded in 2005 and wholly owned by the Austrian Academy of Sciences (ÖAW). Operating from a dedicated research building on the Medical University of Vienna and Vienna General Hospital campus, CeMM conducts post-genomic molecular medicine research aimed at understanding the molecular basis of human diseases in immunology, cancer, metabolic disorders, infections, and aging. Its research outputs span high-impact peer-reviewed publications, open-source computational tools, and a portfolio of biotech spin-offs (Cellzome, Haplogen, Allcyte, Proxygen, Solgate, Postbiotica) generated through a long-running tech-transfer program.
CeMM firmographics
Firmographics- Name
- CeMM
- Legal name
- CeMM Research Center for Molecular Medicine GmbH of the Austrian Academy of Sciences
- Website
- https://cemm.at
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- CeMM is a Vienna-based, ÖAW-owned non-profit research institute conducting post-genomic molecular medicine to elucidate human disease mechanisms, serving the international scientific community via publications, open-source AI tools, and biotech spin-offs.
- Ownership category
- akta.pro rank
CeMM industry classification
Industry- Product category
- Biomedical Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)
Keywords
Where CeMM is headquartered
LocationHeadquarters
- HQ city
- Vienna
- HQ country
- Austria
- HQ region
- Europe
Offices1 record
Markets served
CeMM business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Others
Revenue model
- Government Funding: Primary funding from the Austrian Academy of Sciences (ÖAW), which is 100% shareholder. Core operational funding for basic research institute.
- Research Grants: Competitive research funding including ERC Advanced Grants, Horizon Europe grants, EP PerMed grants, and other European funding programs supporting specific research projects.
- Sponsorship and Donations: Private sponsorship and donations from individuals and organizations supporting CeMM's research and activities, including art facade sponsors and research report supporters.
- Tech Transfer and Licensing: Technology transfer activities including patents and commercialization of research discoveries. Notable spin-offs include Cellzome, Haplogen, Allcyte, Proxygen, and Solgate (founded by Giulio Superti-Furga).
Distribution channels1 record
Marketing channels5 records
CeMM product offering
Product offeringCore offering
CeMM conducts basic and biomedical molecular medicine research, operating state-of-the-art research platforms such as the Molecular Discovery Platform (MDP) and the Biomedical Sequencing Facility (BSF), and developing open-source software tools including LazySlide for AI-driven digital pathology analysis and VRNetzer for immersive molecular network visualization. Its research programs span aging, drug discovery, genomic medicine, clinical science, disease model systems, immunity, and chemistry, with results disseminated through publications, conferences, and tech transfer.
Product overview
CeMM is a basic research institute, not a commercial product company. Its offerings consist of research platforms, facilities, and open-source software tools developed by its researchers. The core research infrastructure includes the Molecular Discovery Platform (MDP) for drug discovery support, the Biomedical Sequencing Facility (BSF) for genomics services, and specialized computational tools like LazySlide for digital pathology analysis using AI. VRNetzer provides immersive visualization of molecular networks. These offerings are made available to researchers through collaborations, publications, and facility access rather than as commercial products.
Differentiator
Problem solved
Functional benefit
Products and services
- LazySlide Open-source AI-driven software tool that enables researchers to analyze whole-slide pathology images using foundation models, connects visual tissue information with molecular data such as gene expression profiles, and allows natural language queries to search tissue images. Aimed at biomedical researchers in digital pathology and computational biology.
- VRNetzer Virtual Reality Network Analysis Platform developed by Jörg Menche's group that allows researchers to dive deep into massive molecular networks behind genetic diseases using VR glasses, visualizing complex protein interaction data. Targeted at biomedical researchers studying disease networks.
- Molecular Discovery Platform (MDP) State-of-the-art CeMM research platform offering access to mass spectrometry, genomics facilities, a deep-sequencing unit, bioinformatics expertise, a chemical biology facility, a virology lab, and imaging and sorting technologies for molecular discovery research. Used by CeMM researchers and collaborators.
- Biomedical Sequencing Facility (BSF) A deep-sequencing unit and genomics facility providing next-generation sequencing services and advanced genomic analysis capabilities to biomedical researchers at and beyond CeMM.
Quantifiable outcome
- High-impact publications in leading journals including Nature Methods, Nature Chemical Biology, Nature Communications, and Cell
- +2 more outcomes
Companies that use CeMM
Customer profileSegments3 records
Ideal customer profiles3 records
CeMM technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature4 records
CeMM partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core, major and minor.
- EU-LIFE AlliancecoreEU-LIFE is an alliance of leading European research institutes in life sciences. CeMM has been a proud member since its creation in 2013, actively contributing to all activities, working groups, projects, and events. CeMM Director Giulio Superti-Furga served as EU-LIFE co-chair (2022-2023) and is current chair (2024-2025). The alliance includes 17 member institutes including Babraham Institute, CRG, Francis Crick Institute, and others.
- Austrian Academy of Sciences (ÖAW)coreThe Austrian Academy of Sciences (ÖAW) is CeMM's parent organization and 100% shareholder. Founded in 1847, ÖAW operates over 25 research institutes and provides the framework for CeMM's independent, innovative, and socially relevant biomedical research.
- Medical University of Vienna (MedUni Vienna)coreCeMM is embedded in the campus of the Medical University of Vienna and Vienna General Hospital, Austria's largest medical research complex. Many Principal Investigators maintain daily collaborations between their medical duties and CeMM research. Several researchers hold joint positions.
- Vienna General Hospital (AKH)coreAustria's largest medical research complex where CeMM is located, enabling close collaboration between basic researchers and clinicians working on predictive, preventive, and personalized medicine.
- AITHYRAmajorAITHYRA is the Research Institute for Biomedical Artificial Intelligence of the Austrian Academy of Sciences, founded in 2024 in Vienna. CeMM CEO Anita Ender is CEO of AITHYRA, and together with Michael Bronstein (founding director), they secured 150 million euros in funding from Boehringer Ingelheim Stiftung.
- Humanitas University / Humanitas Research HospitalmajorMaria Rescigno, CeMM's new Scientific Director (appointed November 2025), was previously Vice-Rector for Research and Deputy Scientific Director at Humanitas University in Milan, where she led the Immunology Program and Laboratory of Mucosal Immunology and Microbiota.
- Horizon Europe / Horizon 2020majorCeMM participates in Horizon Europe Mission Cancer projects including PhotoMel investigating melanoma risk in young adults, and EP PerMed for personalized treatment in children. Multiple researchers are part of these European consortiums.
- St. Anna Children's Cancer Research Institute (St. Anna CCRI)majorResearchers in the Davide Seruggia group work jointly at St. Anna CCRI and CeMM, collaborating on childhood leukemia research and other cancer studies.
- Ludwig Boltzmann GesellschaftminorSuccessful cooperation on rare diseases through the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, and new partnership through Ludwig Boltzmann Institute for Network Medicine for research on biological organization principles.
- Max Perutz Labs / University of ViennamajorJörg Menche, CeMM Adjunct PI, is also affiliated with Uni Vienna/Max Perutz Labs. Collaborations on molecular network research and VRNetzer platform development.
- EMBL (European Molecular Biology Laboratory)majorGiulio Superti-Furga was a postdoctoral fellow and team leader at EMBL until 2004. Multiple collaborations with EMBL institutes continue, and Ewan Birney from EMBL-EBI serves on CeMM's Scientific Advisory Board.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
CeMM competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
CeMM social profiles
Digital presenceCeMM financial estimates
Financial estimateRevenue estimate
Valuation estimate
CeMM leadership team
Management profileNumber of profiles
Profiles2 records
CeMM funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CeMM M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CeMM
What does CeMM do?
CeMM conducts basic and biomedical molecular medicine research, operating state-of-the-art research platforms such as the Molecular Discovery Platform (MDP) and the Biomedical Sequencing Facility (BSF), and developing open-source software tools including LazySlide for AI-driven digital pathology analysis and VRNetzer for immersive molecular network visualization. Its research programs span aging, drug discovery, genomic medicine, clinical science, disease model systems, immunity, and chemistry, with results disseminated through publications, conferences, and tech transfer.
Is CeMM a public or private company?
CeMM is a private company. It is classified as state government owned and is currently operating.
When was CeMM founded?
CeMM was founded in 2005. It employs 101 to 250 people.
Where is CeMM based?
CeMM is headquartered in Vienna, Austria, in the Europe region.
How does CeMM make money?
Four revenue lines are on record. Government Funding is the primary driver. The others are research Grants, sponsorship and Donations and tech Transfer and Licensing.
Does CeMM have an API?
No public API is recorded for CeMM.
What industry is CeMM in?
CeMM's product category is Biomedical Research Services. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 541714 and its SIC code is 8731.